Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26713220
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Bacteriophage
2014 ; 4
(4
): e961869
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Enhancing and initiating phage-based therapies
#MMPMID26713220
Serwer P
; Wright ET
; Chang JT
; Liu X
Bacteriophage
2014[]; 4
(4
): e961869
PMID26713220
show ga
Drug development has typically been a primary foundation of strategy for
systematic, long-range management of pathogenic cells. However, drug development
is limited in speed and flexibility when response is needed to changes in
pathogenic cells, especially changes that produce drug-resistance. The high
replication speed and high diversity of phages are potentially useful for
increasing both response speed and response flexibility when changes occur in
either drug resistance or other aspects of pathogenic cells. We present strategy,
with some empirical details, for (1) using modern molecular biology and
biophysics to access these advantages during the phage therapy of bacterial
infections, and (2) initiating use of phage capsid-based drug delivery vehicles
(DDVs) with procedures that potentially overcome both drug resistance and other
present limitations in the use of DDVs for the therapy of neoplasms. The
discussion of phage therapy includes (a) historical considerations, (b) changes
that appear to be needed in clinical tests if use of phage therapy is to be
expanded, (c) recent work on novel phages and its potential use for expanding the
capabilities of phage therapy and (d) an outline for a strategy that encompasses
both theory and practice for expanding the applications of phage therapy. The
discussion of DDVs starts by reviewing current work on DDVs, including work on
both liposomal and viral DDVs. The discussion concludes with some details of the
potential use of permeability constrained phage capsids as DDVs.
free
free
free
